Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.GW Pharmaceuticals has received notice of allowance (NOA) from the US Patent and Trademark Office (USPTO) for a patent protecing the use of Sativex as a treatment for cancer pain.
Subscribe to our email newsletter
The patent entitled, ‘Pharmaceutical Compositions for the Treatment of Pain,’ covers a method of treating cancer related pain by administering a combination of the cannabinoids cannabidiol (CBD) and delta-9 tetrahydrocannabinol (THC), the two principal cannabinoids in Sativex.
GW Pharma chairman Geoffrey Guy said the grant of this US patent covering Sativex as a treatment for cancer pain is part of a broad platform of intellectual property rights which continue to be developed by GW.
"GW now has 35 patent families as well as other forms of protection such as plant variety rights and proprietary know-how," Guy said.
Sativex is currently in Phase III clinical development as a treatment for cancer pain.
It is approved in the UK, Spain, Czech Republic, Canada and New Zealand as a treatment of multiple sclerosis spasticity.